TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of a Home-based Versus a Hospital-based Outpatient Pulmonary Rehabilitation Program in Patients With COPD: a Multicenter, Randomized Trial
Brief Summary: Short term efficacy of pulmonary rehabilitation for improving functional capacity and quality of life of chronic obstructive respiratory disease (COPD) patient is well known. However, there is an important gap between the scientific knowledge and the clinical use of pulmonary rehabilitation since a a very small number of patients benefit from this therapeutic intervention. We estimate that less than 1% of the 750 000 canadians suffering from COPD have access to a pulmonary rehabilitation program. We want to study the efficacy of a home-based rehabilitation program as a way to facilitate the access to rehabilitation.


Options:
A: Arm Label: Hospital-based; Type: EXPERIMENTAL; Interventions: Behavioral: Pulmonary rehabilitation (teaching and exercise) | Arm Label: Home-Based; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Pulmonary rehabilitation (teaching and exercise) | Intervention Type: BEHAVIORAL; Name: Pulmonary rehabilitation (teaching and exercise); Assigned to Arm(s): Home-Based, Hospital-based
B: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Ususal care | Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: RT management | Intervention Type: OTHER; Name: RT management; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Ususal care; Assigned to Arm(s): Control
C: Arm Label: Disease management program; Type: EXPERIMENTAL; Interventions: Other: Disease Management | Arm Label: Usual site management; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual site management | Intervention Type: OTHER; Name: Disease Management; Assigned to Arm(s): Disease management program | Intervention Type: OTHER; Name: Usual site management; Assigned to Arm(s): Usual site management
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Training with e-health product | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care | Intervention Type: OTHER; Name: Training with e-health product; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Control

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: VIP: Vascular Imaging Project. Prospective Randomized Study on the Effect of AUC-monitored Treatment With Steroids Combined With Either a Calcineurin Inhibitor or Mycophenolate Mofetil on the Progression of Subclinical Cardiovascular Disease in Renal Transplant Recipients.
Brief Summary: This is a prospective randomized study to compare the influence of area under the curve (AUC)-monitored dual treatment with steroids in combination with either a calcineurin inhibitor (CNI) or mycophenolate mofetil (MMF) on the progression of subclinical cardiovascular disease in renal transplant recipients.

Since CNI have a detrimental effect on cardiovascular risk factors, it is the researchers' hypothesis that renal recipients after CNI withdrawal will have more reduction of markers of cardiovascular disease.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: AUC monitored withdrawal of MMF or CNI | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: AUC monitored withdrawal of MMF or CNI | Intervention Type: DRUG; Name: AUC monitored withdrawal of MMF or CNI; Assigned to Arm(s): 1, 2
B: Arm Label: CNI standard regimen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Myfortic, Drug: Sandimmun Optoral, Drug: Simulect® | Arm Label: CNI free regimen; Type: EXPERIMENTAL; Interventions: Drug: Everolimus, Drug: Myfortic, Drug: Sandimmun Optoral | Arm Label: CNI low regimen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Everolimus, Drug: Sandimmun Optoral | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): CNI free regimen, CNI low regimen | Intervention Type: DRUG; Name: Myfortic; Assigned to Arm(s): CNI free regimen, CNI standard regimen | Intervention Type: DRUG; Name: Sandimmun Optoral; Assigned to Arm(s): CNI free regimen, CNI low regimen, CNI standard regimen | Intervention Type: DRUG; Name: Simulect®; Assigned to Arm(s): CNI standard regimen
C: Intervention Type: DRUG; Name: Sirolimus; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: cyclosporine; Assigned to Arm(s): N/A
D: Arm Label: Everolimus + Mycophenolate sodium; Type: EXPERIMENTAL; Interventions: Drug: Everolimus, Drug: Enteric-coated mycophenolate sodium, Drug: Corticosteroids | Arm Label: Cyclosporine + Mycophenolate sodium; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cyclosporine, Drug: Enteric-coated mycophenolate sodium, Drug: Corticosteroids | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Everolimus + Mycophenolate sodium | Intervention Type: DRUG; Name: Cyclosporine; Assigned to Arm(s): Cyclosporine + Mycophenolate sodium | Intervention Type: DRUG; Name: Enteric-coated mycophenolate sodium; Assigned to Arm(s): Cyclosporine + Mycophenolate sodium, Everolimus + Mycophenolate sodium | Intervention Type: DRUG; Name: Corticosteroids; Assigned to Arm(s): Cyclosporine + Mycophenolate sodium, Everolimus + Mycophenolate sodium

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Use of Aerosolized rhDNase (Pulmozyme®) in Emergency Department Adults With Refractory Acute Asthma: A Pilot Study
Brief Summary: Even with current standard ED treatments 20-25% of patients presenting to the ED with an acute asthma episode will still require hospitalization. For patients unresponsive to beta-agonists the admit rates will be higher. Of those well enough to be discharged from the ED nearly 30% will relapse within one month. More than 5,000 patients with asthma still die each year in the USA. For patients who do not respond to beta-agonists, there are relatively few treatment options for rapid improvement of symptoms and pulmonary function. Presumably, mucous secretion and plugging play an important role in the pathogenesis of severe asthma unresponsive to beta-agonists. The use of agents to promote clearance of intra-luminal secretions and mucous plugs may represent an important advance in the management of acutely ill asthmatics, both to hasten recovery and prevent deterioration in the acute care setting and to prevent relapse after discharge from the ED.

OBJECTIVES

2.1 Study Hypothesis: rhDNAse can be safely used in patients presenting to the Emergency Department with acute moderate-severe asthma who do not have adequate responses to beta-agonists

Project Specific Aim: This is a pilot study to determine the safety of three different doses of pulmozyme® (2.5mg, 5.0mg and 7.5mg) in patients presenting to the ED with acute asthma. In addition to safety trends for improvement in pulmonary function and clinical outcomes will be monitored and data analyzed. Based on the safety profile and observable responses to treatment, this information may be used to develop larger trials to determine the efficacy and dosing strategy for treating acutely ill asthmatics with rhDNAse.


Options:
A: Intervention Type: DRUG; Name: rhDNAse (pulmozyme); Assigned to Arm(s): N/A
B: Intervention Type: DEVICE; Name: Integrated Care Pathway; Assigned to Arm(s): N/A
C: Arm Label: A1; Type: ACTIVE_COMPARATOR; Interventions: Drug: montelukast | Arm Label: A2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: montelukast; Assigned to Arm(s): A1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A2
D: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Comparator: placebo (unspecified) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: montelukast sodium | Intervention Type: DRUG; Name: montelukast sodium; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Comparator: placebo (unspecified); Assigned to Arm(s): 1

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The CAPISCE-Trial: Community-Acquired Pneumonia; an Intervention Study With Corticosteroids
Brief Summary: The purpose of this study is to determine the efficacy of addition of corticosteroid therapy to antibiotics in patient admitted with Community-acquired pneumonia.

The hypothesis is: Prednisolone in combination with antibiotic treatments is effective in improving clinical outcome in patients hospitalized with CAP.


Options:
A: Intervention Type: DRUG; Name: prednisone; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: dexamethasone | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: dexamethasone | Intervention Type: DRUG; Name: dexamethasone; Assigned to Arm(s): 1, 2
C: Arm Label: Prednisone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prednisone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Prednisone | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Placebo, Prednisone
D: Arm Label: methylprednisolone; Type: EXPERIMENTAL; Interventions: Drug: methylprednisolone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: methylprednisolone; Assigned to Arm(s): methylprednisolone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The CAPISCE-Trial: Community-Acquired Pneumonia; an Intervention Study With Corticosteroids
Brief Summary: The purpose of this study is to determine the efficacy of addition of corticosteroid therapy to antibiotics in patient admitted with Community-acquired pneumonia.

The hypothesis is: Prednisolone in combination with antibiotic treatments is effective in improving clinical outcome in patients hospitalized with CAP.


Options:
A: Intervention Type: DRUG; Name: prednisone; Assigned to Arm(s): N/A
B: Arm Label: Experimental Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: methylprednisolone | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal Saline (0.9%) | Intervention Type: DRUG; Name: methylprednisolone; Assigned to Arm(s): Experimental Group | Intervention Type: DRUG; Name: Normal Saline (0.9%); Assigned to Arm(s): Placebo Group
C: Arm Label: Hydrocortisone; Type: EXPERIMENTAL; Interventions: Drug: Hydrocortisone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Hydrocortisone; Assigned to Arm(s): Hydrocortisone
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: hydrocortisone | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: hydrocortisone, Drug: fludrocortisone | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: recombinant human insulin, Drug: hydrocortisone | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: recombinant human insulin, Drug: hydrocortisone, Drug: fludrocortisone | Intervention Type: DRUG; Name: recombinant human insulin; Assigned to Arm(s): 3, 4 | Intervention Type: DRUG; Name: hydrocortisone; Assigned to Arm(s): 1, 2, 3, 4 | Intervention Type: DRUG; Name: fludrocortisone; Assigned to Arm(s): 2, 4 | Intervention Type: DRUG; Name: Hydrocortisone; Assigned to Arm(s): 1

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The CAPISCE-Trial: Community-Acquired Pneumonia; an Intervention Study With Corticosteroids
Brief Summary: The purpose of this study is to determine the efficacy of addition of corticosteroid therapy to antibiotics in patient admitted with Community-acquired pneumonia.

The hypothesis is: Prednisolone in combination with antibiotic treatments is effective in improving clinical outcome in patients hospitalized with CAP.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: hydrocortisone | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: hydrocortisone, Drug: fludrocortisone | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: recombinant human insulin, Drug: hydrocortisone | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: recombinant human insulin, Drug: hydrocortisone, Drug: fludrocortisone | Intervention Type: DRUG; Name: recombinant human insulin; Assigned to Arm(s): 3, 4 | Intervention Type: DRUG; Name: hydrocortisone; Assigned to Arm(s): 1, 2, 3, 4 | Intervention Type: DRUG; Name: fludrocortisone; Assigned to Arm(s): 2, 4 | Intervention Type: DRUG; Name: Hydrocortisone; Assigned to Arm(s): 1
B: Intervention Type: DRUG; Name: prednisone; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: dexamethasone | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: dexamethasone | Intervention Type: DRUG; Name: dexamethasone; Assigned to Arm(s): 1, 2
D: Arm Label: EN only; Type: EXPERIMENTAL; Interventions: Other: Withholding PN during the first week of ICU stay | Arm Label: EN plus early PN; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E | Intervention Type: OTHER; Name: Withholding PN during the first week of ICU stay; Assigned to Arm(s): EN only | Intervention Type: DRUG; Name: Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E; Assigned to Arm(s): EN plus early PN

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Value of Antibiotic Treatment of Exacerbations of Hospitalised COPD Patients
Brief Summary: The role of antibiotic therapy in patients with COPD remains controversial. While the outcome of several clinical trials is in favour of antibiotics, the quality of these studies in insufficient. In this study the efficacy of doxycycline is compared to placebo. All concommitant treatment (steroids, bronchodilator therapy, physiotherapy) is standardized.

The investigators hypothesize that patients with an acute exacerbations will have a better outcome when treated with antibiotics.


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Avelox (Moxifloxacin, BAY12-8039) | Arm Label: Arm 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Avelox (Moxifloxacin, BAY12-8039); Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm 2
B: Arm Label: lactose pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Sultamicillin; Type: EXPERIMENTAL; Interventions: Drug: Sultamicillin | Intervention Type: DRUG; Name: Sultamicillin; Assigned to Arm(s): Sultamicillin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): lactose pill
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Amoxycillin and clavulanic acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amoxicillin and clavulanic acid | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Amoxicillin and clavulanic acid; Assigned to Arm(s): Amoxycillin and clavulanic acid
D: Intervention Type: DRUG; Name: doxycycline; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluating the Impact of Computer-Based Decision Support for the Management of Asthma in Primary Care
Brief Summary: Asthma is a health problem that afflicts many Canadians. Better methods are needed to provide primary care physicians with ways of implementing current guidelines into regular practice for optimal disease management. This study will test the benefits of providing computer-based decision-support for asthma to primary care physicians, with links to home monitoring for their patients. To add value and to ensure regular use for the physician for all of his/her patients, these computerized decision-support tools will be linked to an electronic prescribing and drug management system. The investigators will evaluate the effectiveness of the computer-based decision-support system by determining whether asthma patients of physicians who receive computer-assisted management tools have better disease control after 33 months of implementation compared to asthma patients of physicians who have the electronic prescription and drug management system alone. To answer this question, the investigators will conduct a cluster randomized controlled trial in a population of approximately 100 physicians in 40 clinics in Quebec, and a total of approximately 4500 of their patients with asthma.


Options:
A: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Device: computer-based decision support for asthma management | Intervention Type: DEVICE; Name: computer-based decision support for asthma management; Assigned to Arm(s): 2
B: Arm Label: e-POCT; Type: EXPERIMENTAL; Interventions: Other: Management of febrile children using e-POCT | Arm Label: ALMANACH; Type: ACTIVE_COMPARATOR; Interventions: Other: Management of febrile children using ALMANACH | Arm Label: Routine practice; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Management of febrile children using e-POCT; Assigned to Arm(s): e-POCT | Intervention Type: OTHER; Name: Management of febrile children using ALMANACH; Assigned to Arm(s): ALMANACH
C: Arm Label: Educational intervention; Type: EXPERIMENTAL; Interventions: Other: Educational intervention | Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Educational intervention; Assigned to Arm(s): Educational intervention
D: Arm Label: Academic Detailing (AD); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: AD + Integrated Tobacco Order Set; Type: EXPERIMENTAL; Interventions: Other: AD + Integrated Tobacco Order Set | Intervention Type: OTHER; Name: AD + Integrated Tobacco Order Set; Assigned to Arm(s): AD + Integrated Tobacco Order Set

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Multicenter, Open Label, Randomized Study of the Safety, Tolerability and Efficacy of Everolimus (RAD001) With Basiliximab, Corticosteroids and Lower Levels Versus Higher Levels of Tacrolimus in de Novo Renal Transplant Recipients
Brief Summary: This study will assess the safety and efficacy of everolimus with basiliximab, corticosteroids and lower levels versus higher levels of tacrolimus in de novo renal transplant recipients.


Options:
A: Intervention Type: DRUG; Name: Mycophenolate mofetil withdrawal; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Cyclosporione A withdrawal; Assigned to Arm(s): N/A
B: Arm Label: Calcineurin free; Type: EXPERIMENTAL; Interventions: Drug: Sirolimus, Drug: Prednisone, Drug: Mycophenolate mofetil, Procedure: Protocol biopsies | Arm Label: Calcineurin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cyclosporine A, Drug: Prednisone, Drug: Mycophenolate mofetil, Procedure: Protocol biopsies | Intervention Type: DRUG; Name: Sirolimus; Assigned to Arm(s): Calcineurin free | Intervention Type: DRUG; Name: Cyclosporine A; Assigned to Arm(s): Calcineurin | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Calcineurin, Calcineurin free | Intervention Type: DRUG; Name: Mycophenolate mofetil; Assigned to Arm(s): Calcineurin, Calcineurin free | Intervention Type: PROCEDURE; Name: Protocol biopsies; Assigned to Arm(s): Calcineurin, Calcineurin free
C: Arm Label: Everolimus + Reduced dose of cyclosporine; Type: EXPERIMENTAL; Interventions: Drug: Everolimus, Drug: Basiliximab, Drug: Cyclosporine A, Drug: Corticosteroid | Arm Label: Mycophenolate mofetil (MMF) + Standard dose of cyclosporine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mycophenolate mofetil (MMF), Drug: Basiliximab, Drug: Cyclosporine A, Drug: Corticosteroid | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Everolimus + Reduced dose of cyclosporine | Intervention Type: DRUG; Name: Mycophenolate mofetil (MMF); Assigned to Arm(s): Mycophenolate mofetil (MMF) + Standard dose of cyclosporine | Intervention Type: DRUG; Name: Basiliximab; Assigned to Arm(s): Everolimus + Reduced dose of cyclosporine, Mycophenolate mofetil (MMF) + Standard dose of cyclosporine | Intervention Type: DRUG; Name: Cyclosporine A; Assigned to Arm(s): Everolimus + Reduced dose of cyclosporine, Mycophenolate mofetil (MMF) + Standard dose of cyclosporine | Intervention Type: DRUG; Name: Corticosteroid; Assigned to Arm(s): Everolimus + Reduced dose of cyclosporine, Mycophenolate mofetil (MMF) + Standard dose of cyclosporine
D: Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Multicenter, Open Label, Randomized Study of the Safety, Tolerability and Efficacy of Everolimus (RAD001) With Basiliximab, Corticosteroids and Lower Levels Versus Higher Levels of Tacrolimus in de Novo Renal Transplant Recipients
Brief Summary: This study will assess the safety and efficacy of everolimus with basiliximab, corticosteroids and lower levels versus higher levels of tacrolimus in de novo renal transplant recipients.


Options:
A: Arm Label: 1 Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Simulect (basliximab) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Biological: Thymoglobulin [Anti-thymocyte Globulin (rabbit)] | Intervention Type: BIOLOGICAL; Name: Thymoglobulin [Anti-thymocyte Globulin (rabbit)]; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Simulect (basliximab); Assigned to Arm(s): 1 Control
B: Intervention Type: DRUG; Name: daclizumab; Assigned to Arm(s): N/A
C: Arm Label: Basiliximab; Type: EXPERIMENTAL; Interventions: Drug: basiliximab, MMF(mycophenolate mofetil), cyclosporine, prednisone (or equivalent) | Arm Label: Basiliximab-free; Type: ACTIVE_COMPARATOR; Interventions: Drug: MMF, cyclosporine, steroids | Intervention Type: DRUG; Name: basiliximab, MMF(mycophenolate mofetil), cyclosporine, prednisone (or equivalent); Assigned to Arm(s): Basiliximab | Intervention Type: DRUG; Name: MMF, cyclosporine, steroids; Assigned to Arm(s): Basiliximab-free
D: Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): N/A

Answer: D